News and Events

Clinical trial researching combination therapy for solid tumors

A trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, is researching white blood cell gene therapy and vaccine therapy for certain metastatic cancers.

Three CCR researchers elected to the National Academy of Sciences

Steven A. Rosenberg, M.D, Ph.D., Chief of the Surgery Branch, Giorgio Trinchieri, M.D., Chief of the Laboratory of Integrative Cancer Immunology, and Sandra L. Wolin, M.D., Ph.D., Chief of the RNA Biology Laboratory, were elected as 2024 members of the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research. The Academy is committed to furthering science in America, and its members are outstanding contributors to the international scientific community.

Clinical trial researching detection methods for multiple myeloma

A trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is studying a radiotracer that may be a useful detection method for multiple myeloma.

Jung-Min Lee elected to the American Society for Clinical Investigation

Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, was elected to the American Society for Clinical Investigation. The organization seeks to support scientific efforts, educational needs and clinical aspirations of physician-scientists to improve the health of all people. Lee was selected for her merit as an internationally recognized expert in ovarian cancer and for being a highly respected clinician and physician-scientist.

CCR researchers receive a range of HHS awards

Three CCR researchers received prestigious awards from the Department of Health and Human Services. They are being recognized for their excellence, dedication and achievements in their respective research fields.

CCR researchers elected to the Association of American Physicians

Elaine S. Jaffe, M.D., NIH Distinguished Investigator in the Laboratory of Pathology, and Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch, were elected as 2024 members of the Association of American Physicians. The organization seeks to inspire physician-led research across all fields of science and medicine to improve patient health care and the health of Americans.

Celebrating CCR Careers: Mark Gilbert, M.D.

Mark Gilbert, M.D., has been a neuro-oncologist for nearly four decades, working to find better treatments for people with rare brain and spine tumors. After nearly a decade at CCR as Chief of the Neuro-Oncology Branch, he is announcing his retirement.

NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients

In a proof-of-concept study published on April 18, 2024, in Nature Cancer, CCR researchers have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug. The team, led by Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, suggests that such single-cell RNA sequencing data could one day be used to help doctors more precisely match cancer patients with drugs that will be effective in treating their cancer.

Jung-Min Lee appointed Senior Investigator at CCR

The CCR community congratulates Jung-Min Lee, M.D., who has been appointed as a Senior Investigator in the Women’s Malignancies Branch. Lee’s research focuses on developing targeted therapies for ovarian carcinoma. Her studies have identified key proteins of DNA damage response pathways as therapeutic targets, opening up possibilities for novel therapies for this disease. Her research also emphasizes the collection of patient samples to better understand treatment response and tumor biology.

Clinical trial researching medication therapy for IDH2-mutated nasal cavity or skull base tumors

A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching targeted medication therapy for patients with IDH2-mutated tumors in the nasal cavity or skull base area.

Breadcrumb